Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-08-30

Clinical Trial Update: TRUST Study: Raptiva ® in Hand & Foot Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update for Raptiva (efalizumab) in hand and foot psoriasis shows the study was terminated. Results were posted on 2010-08-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Chronic Plaque Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2010-08-30